The use of hormone therapy in survivors of breast cancer is complex and contentious. Historically, guidelines have strongly advised against using hormone therapy. Its safety likely depends on many factors. However, long-term oncologic data are lacking, leaving women with unresolved quality-of-life and health concerns and practitioners uncertain about their recommendations. In the short term, there will not be definitive data, and decisions must be made based on the existing imperfect evidence.
Holly J. Pederson (Tue,) studied this question.